A Phase 2b, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Safety and Efficacy of Rifalazil (25 Milligram) Compared With Azithromycin (1 Gram) for the Treatment of Uncomplicated Genital Chlamydia Trachomatis Infection in Women

Trial Profile

A Phase 2b, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Safety and Efficacy of Rifalazil (25 Milligram) Compared With Azithromycin (1 Gram) for the Treatment of Uncomplicated Genital Chlamydia Trachomatis Infection in Women

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2014

At a glance

  • Drugs Rifalazil (Primary) ; Azithromycin
  • Indications Chlamydial infections
  • Focus Therapeutic Use
  • Sponsors ActivBiotics
  • Most Recent Events

    • 01 Apr 2013 Status changed from recruiting to completed as reported ClinicalTrials.gov.
    • 04 Jul 2012 New trial record
    • 01 Jul 2012 Status changed from not yet recruiting to recruiting as reported ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top